The Western Cape and parts of the Northern Cape are set to be battered by heavy rain, gusting winds and a possible dusting of snow from Thursday into the weekend, the South African Weather Service says. The weather service said on Monday that winds as high as 75km/h were set to hit parts of the Northern…
Researchers at the University of KwaZulu-Natal with the ILEX Genehecker. It will help improve the turnaround time for Covid-19 testing. New instrumentation will help UKZN reduce its turnaround time for testing from 24 hours to just six.The device is worth about $10 000 or R170 000.It was donated to the university by Gift of the…
By Nick Brown, Deena Beasley, Gabriela Mello and Alexander Cornwell(Reuters) - Dr. Gopi Patel recalls how powerless she felt when New York's Mount Sinai Hospital overflowed with COVID-19 patients in March.Guidance on how to treat the disease was scant, and medical studies were being performed so hastily they couldn’t always be trusted."You felt very helpless,”…
The Special Investigating Unit has closed three of its offices with immediate effect after an employee tested positive for Covid-19. Thomas Trutschel/Photothek via Getty Images The Special Investigating Unit (SIU) has closed three of its offices with immediate effect after an employee tested positive for Covid-19. Its head office, the Gauteng provincial office in Pretoria and…
(Reuters) - One night in April, as coronavirus swept through the Hammonton Center for Rehabilitation and Healthcare, Robyn Esaw, a double amputee, signaled for help with her bedpan. She said she hit the bedside button that turns on a red hallway light. None of the few remaining staff showed up - and one of them…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f